(Q36214689)

12 August 2017

1 reference

title

Inhaled salmeterol/fluticasone propionate: a review of its use in asthma (English)

1 reference

Katherine A Lyseng-Williamson

12 August 2017

1 reference

series ordinal

2

object named as

Katherine A Lyseng-Williamson

1 reference

12 August 2017

Neil A Reynolds

1

1 reference

12 August 2017

Lynda R Wiseman

series ordinal

3

1 reference

12 August 2017

publication date

1 January 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

65

1 reference

12 August 2017

issue

12

1 reference

12 August 2017

page(s)

1715-1734

1 reference

Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma

12 August 2017

cites work

1 reference

12 December 2020

Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma

1 reference

12 December 2020

Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study

1 reference

12 December 2020

Efficacy and Safety of Salmeterol/Fluticasone Propionate Combination Delivered by the Diskustrade mark or Pressurised Metered-Dose Inhaler in Children with Asthma

1 reference

12 December 2020

Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions

1 reference

12 December 2020

Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma

1 reference

12 December 2020

Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists

1 reference

12 December 2020

Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 microg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma

1 reference

12 December 2020

Combination therapy of long-acting beta2-adrenoceptor agonists and corticosteroids for asthma.

1 reference

12 December 2020

Impact of inhaled salmeterol/fluticasone propionate combination product versus budesonide on the health-related quality of life of patients with asthma

1 reference

12 December 2020

Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies

1 reference

12 December 2020

Salmeterol/fluticasone propionate (50/250 microg) combination is superior to double dose fluticasone (500 microg) for the treatment of symptomatic moderate asthma

1 reference

12 December 2020

The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma

1 reference

12 December 2020

Is overall asthma control being achieved? A hypothesis-generating study

1 reference

12 December 2020

The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma

1 reference

12 December 2020

Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma

1 reference

12 December 2020

Salmeterol/fluticasone propionate (50/100 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma

1 reference

12 December 2020

Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids

1 reference

12 December 2020

Effect of fluticasone/salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent asthma

1 reference

12 December 2020

Efficacy and safety of fluticasone propionate 44 μg/salmeterol 21 μg administeredin a hydrofluoroalkane metered-dose inhaleras an initial asthma maintenance treatment

1 reference

12 December 2020

Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma

1 reference

12 December 2020

Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma

1 reference

12 December 2020

Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys

1 reference

12 December 2020

Asthma. From bronchoconstriction to airways inflammation and remodeling

1 reference

12 December 2020

Salmeterol/fluticasone propionate combination therapy 50/250 microg twice daily is more effective than budesonide 800 microg twice daily in treating moderate to severe asthma

1 reference

12 December 2020

Salmeterol/Fluticasone combination inhaler: a new, effective and well tolerated treatment for asthma

1 reference

12 December 2020

Steroid-sparing effects of fluticasone propionate 100 microg and salmeterol 50 microg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 microg administered twice daily

1 reference

12 December 2020

Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent asthma

1 reference

12 December 2020

The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persiste

1 reference

12 December 2020

Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma

1 reference

12 December 2020

Evaluation of different inhaled combination therapies (EDICT): a randomised, double-blind comparison of Seretide (50/250 microg bd Diskus vs. formoterol (12 microg bd) and budesonide (800 microg bd) given concurrently (both via Turbuhaler) in patien

1 reference

12 December 2020

Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma

1 reference

12 December 2020

Salmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma

1 reference

12 December 2020

Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 microg twice daily and budesonide 800 microg twice daily in the treatment of adults and adolescents with asthma. International Study Group

1 reference

12 December 2020

Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast

1 reference

12 December 2020

Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers

1 reference

12 December 2020

Development of an economic model to assess the cost effectiveness of asthma management strategies

1 reference

12 December 2020

Initiation of maintenance treatment of persistent asthma: salmeterol/fluticasone propionate combination treatment is more effective than inhaled steroid alone

1 reference

12 December 2020

Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages < or = 500 microg/day in adults and adolescents with mild to moderate asthma

1 reference

12 December 2020

Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta(2)-agonists alone

1 reference

12 December 2020

Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers

1 reference

12 December 2020

10.2165/00003495-200565120-00012

Identifiers

DOI

1 reference

Dimensions Publication ID

12 August 2017

1041363659

0 references

1 reference